Literature DB >> 28018500

The Effect of Hachimi-Jio-Gan (Ba-Wei-Di-Huang-Wan) on the Quality of Life in Patients with Peripheral Arterial Disease - A Prospective Study Using Kampo Medicine.

Koji Kawago1, Shunya Shindo1, Hidenori Inoue1, Junetsu Akasaka1, Shinya Motohashi1, Go Urabe1, Masahiro Sato1, Hirotomo Uchiyama1, Hitoshi Ogino2.   

Abstract

Objective: To assess whether Hachimi-jio-gan (HJG), a preparation of Kampo medicine (traditional Japanese medicine), improves quality of life (QOL) in patients with peripheral arterial disease (PAD). Materials and
Methods: Among the patients with PAD being followed in the Department of Cardiovascular Surgery at Tokyo Medical University Hachioji Medical Center, those with intermittent claudication (IC) and in stable condition regarding PAD severity were registered. We registered the patients from April 2014 to March 2015. We administered HJG extract for 6 months to the patients. The primary endpoint was Walking Impairment Questionnaire (WIQ) score, which was approved as an indicator of QOL of the patient with PAD. We assessed WIQ score both before and after administration of the HJG.
Results: We analyzed 14 patients. WIQ items of pain, distance, and speed improved significantly. Furthermore, the median of the total score of WIQ improved significantly from 162.5 points to 308.0 points. All patients showed improvement in the total score and 7 patients out of 14 patients (50%) showed a remarkably effective improvement in score of more than 100 points.
Conclusion: HJG might improve the QOL in patients with IC due to PAD.

Entities:  

Keywords:  Ba-Wei-Di-Huang-Wan; Hachimi-jio-gan; PAD; cilostazol; intermittent claudication

Year:  2016        PMID: 28018500      PMCID: PMC5174988          DOI: 10.3400/avd.oa.15-00133

Source DB:  PubMed          Journal:  Ann Vasc Dis        ISSN: 1881-641X


  9 in total

1.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

2.  Validation of the Dutch version of the Walking Impairment Questionnaire.

Authors:  M Verspaget; S P A Nicolaï; L M Kruidenier; R J Th J Welten; M H Prins; J A W Teijink
Journal:  Eur J Vasc Endovasc Surg       Date:  2008-11-12       Impact factor: 7.069

Review 3.  Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication.

Authors:  Michael S Conte; Frank B Pomposelli; Daniel G Clair; Patrick J Geraghty; James F McKinsey; Joseph L Mills; Gregory L Moneta; M Hassan Murad; Richard J Powell; Amy B Reed; Andres Schanzer; Anton N Sidawy
Journal:  J Vasc Surg       Date:  2015-01-28       Impact factor: 4.268

4.  Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.

Authors:  Judith G Regensteiner; John E Ware; Walter J McCarthy; Peter Zhang; William P Forbes; Jeffrey Heckman; William R Hiatt
Journal:  J Am Geriatr Soc       Date:  2002-12       Impact factor: 5.562

5.  Anti-thrombic actions of 70% methanolic extract and cinnamic aldehyde from cinnamomi cortex.

Authors:  H Matsuda; R Matsuda; S Fukuda; H Shiomoto; M Kubo
Journal:  Chem Pharm Bull (Tokyo)       Date:  1987-03       Impact factor: 1.645

6.  Effect of lower extremity blood pressure on physical functioning in patients who have intermittent claudication. The Chicago Claudication Outcomes Research Group.

Authors:  J Feinglass; W J McCarthy; R Slavensky; L M Manheim; G J Martin
Journal:  J Vasc Surg       Date:  1996-10       Impact factor: 4.268

7.  Claudication distances and the Walking Impairment Questionnaire best describe the ambulatory limitations in patients with symptomatic peripheral arterial disease.

Authors:  Sara A Myers; Jason M Johanning; Nick Stergiou; Thomas G Lynch; G Matthew Longo; Iraklis I Pipinos
Journal:  J Vasc Surg       Date:  2008-01-22       Impact factor: 4.268

8.  Effects of the 5-HT2A Antagonist Sarpogrelate on Walking Ability in Patients with Intermittent Claudication as Measured Using the Walking Impairment Questionnaire.

Authors:  Hiroshi Matsuo; Hiroshi Shigematsu
Journal:  Ann Vasc Dis       Date:  2008-09-25

9.  [Analgesic effects of Tsumura-shuuji-bushi-matsu and mesaconitine].

Authors:  Y Takizawa; T Isono; Y Suzuki; Y Hayakawa; T Oyama
Journal:  Nihon Yakurigaku Zasshi       Date:  1992-10
  9 in total
  3 in total

1.  Protective effect of Palmijihwanghwan in a mouse model of cigarette smoke and lipopolysaccharide-induced chronic obstructive pulmonary disease.

Authors:  Eun Bok Baek; Jin-Hyung Rho; Eunhye Jung; Chang-Seob Seo; Jin-Hee Kim; Hyo-Jung Kwun
Journal:  BMC Complement Med Ther       Date:  2021-11-16

Review 2.  Kampo Medicines for Frailty in Locomotor Disease.

Authors:  Hajime Nakae; Yuko Hiroshima; Miwa Hebiguchi
Journal:  Front Nutr       Date:  2018-04-26

3.  Japanese traditional herbal medicine reduces use of pregabalin and opioids for pain in patients with lumbar spinal canal stenosis: a retrospective cohort study.

Authors:  Mitsuhiko Oohata; Yuko Aoki; Michiko Miyata; Hiroki Mizobe; Kenji S Suzuki
Journal:  JA Clin Rep       Date:  2017-10-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.